Pure Global
NCT06406439

DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

A Multicenter, Open Label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in Patients With Type 1, Type 2 or Pancreatogenic Diabetes Mellitus Under Multiple Dose Insulin Therapy
G2e Co., Ltd·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Mellitus
Drug/Device/Intervention
Smart Insulin Pen
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
G2e Co., Ltd
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
May 09, 2024
End date
Dec 01, 2024
Enrollment
120 participants
Primary outcome

Change in HbA1c(%) at 12 weeks compared to baseline

Summary

A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety
 of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic
 Diabetes Mellitus under Multiple Dose Insulin Therapy

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsUnspecified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06406439
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06406439 through Pure Global AI's free database. This phase not specified trial is sponsored by G2e Co., Ltd and is currently Recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.